Related Experiment Video
Updated: Jul 10, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
8.2K
Determining optimal pretreatment in cardiac surgery: an experimental study
Masahiro Fujii1, Hiromasa Yamashita2, Yasuhiro Kawase2
1Department of Cardiovascular Surgery, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba, 270-1694, Japan. m-fujii@nms.ac.jp.
General Thoracic and Cardiovascular Surgery
|November 14, 2024
Summary
Esaxerenone and sacubitril/valsartan improved heart function recovery after cardioplegic arrest in rats. Both drugs reduced myocardial injury, suggesting they offer protection against damage from cardiac procedures.
Area of Science:
- Cardiology
- Pharmacology
- Cardiovascular Surgery
Background:
- Current heart failure treatments include four drug classes, improving survival.
- Cardioplegic arrest during surgery can cause myocardial damage.
Purpose of the Study:
- To investigate the myocardial protective effects of esaxerenone and sacubitril/valsartan against cardioplegic arrest.
- To assess if these drugs can counteract harm caused by cardiac arrest procedures.
Main Methods:
- Male Wistar rats were treated with esaxerenone or sacubitril/valsartan for two weeks.
- Isolated rat hearts underwent cardioplegia and global ischemia followed by reperfusion.
- Functional recovery and troponin T levels were measured to assess myocardial injury.
Main Results:
- Esaxerenone and sacubitril/valsartan groups showed significantly improved recovery of left ventricular developed pressure compared to controls.
- Troponin T levels, a marker of myocardial injury, were significantly lower in the drug-treated groups.
Conclusions:
- Pre-treatment with esaxerenone or sacubitril/valsartan enhances myocardial protection during cardioplegic arrest.
- These drugs may attenuate myocardial injury associated with hyperkalemic cardioplegic arrest.
